Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding insider trading activity rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It contains specific transaction data related to a single insider trade:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Price: $44.190 per ADS
- Transaction Volume: 26.288 ADSs
- Transaction Date: July 18, 2016
- Exchange: NYSE (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of ADSs by a person closely associated with a Principal Director or Manager (PDMR).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed following the re-investment of dividends paid to shareholders on July 14, 2016.
Investor Verification Points
- Verify the identity of the insider: Dr. K. Slaoui, identified as a person closely associated with Dr. M. M. Slaoui (Chairman, Global Vaccines).
- Confirm the transaction nature: Acquisition of ADSs via dividend re-investment.
- Note the filing date: July 19, 2016, with the transaction occurring on July 18, 2016.
- Recognize that this filing does not contain quarterly or annual financial performance data.